HSA-TRX

HSA-TRX is a recombinant fusion protein composed of **human thioredoxin-1 (Trx)** genetically fused to **human serum albumin (HSA)**, designed to significantly extend the plasma half-life of Trx for therapeutic use. The fusion increases circulatory retention and enhances distribution to organs including kidney, lung, and liver. Trx is a redox-active protein with anti-oxidative and anti-inflammatory properties, but its clinical application is limited by short half-life due to rapid renal clearance. HSA-TRX maintains the biological functions of Trx, including reduction of oxidative stress and inflammation (via suppression of **macrophage migration inhibitory factor** and pro-inflammatory cytokines **TNF-α** and **IL-6**), and inhibition of cell apoptosis. In preclinical models, HSA-TRX has demonstrated efficacy in preventing and treating various forms of **acute kidney injury (AKI)** (including rhabdomyolysis-induced, contrast-induced, and ischemia-reperfusion), **cardiotoxicity** induced by agents such as doxorubicin, and systemic inflammatory or oxidative stress-related organ injuries. Its mechanism of action involves *scavenging reactive oxygen species*, *modulating inflammatory mediators*, and *suppressing apoptosis in stressed tissues*.

Brand names

HSA-TRX

Other names

human serum albumin-thioredoxin fusion proteinHSA-Trxalbumin fused thioredoxinlong-acting thioredoxin